Research ArticleChemotherapy, Antibiotics, and Gene Therapy
DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110α (H1047R)
Jia-li Liu, Guo-rui Gao, Xi Zhang, Su-fen Cao, Chen-liang Guo, Xiang Wang, Lin-jiang Tong, Jian Ding, Wen-hu Duan and Ling-hua Meng
Journal of Pharmacology and Experimental Therapeutics March 2014, 348 (3) 432-441; DOI: https://doi.org/10.1124/jpet.113.210724
Jia-li Liu
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Guo-rui Gao
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Xi Zhang
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Su-fen Cao
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Chen-liang Guo
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Xiang Wang
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Lin-jiang Tong
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Jian Ding
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Wen-hu Duan
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
Ling-hua Meng
Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research (J.-l.L., X.Z., C.-l.G., X.W., L-j.T., J.D., L-h.M.) and Department of Medicinal Chemistry (W-h.D.), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China; and School of Pharmacy, East China University of Science and Technology, Shanghai, P.R. China (G.-r.G., S.-f.C. W.-h.D.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
A Selective PI3K Inhibitor Preferentially Inhibits p110α (H1047R) Mutated Cells
Jia-li Liu, Guo-rui Gao, Xi Zhang, Su-fen Cao, Chen-liang Guo, Xiang Wang, Lin-jiang Tong, Jian Ding, Wen-hu Duan and Ling-hua Meng
Journal of Pharmacology and Experimental Therapeutics March 1, 2014, 348 (3) 432-441; DOI: https://doi.org/10.1124/jpet.113.210724
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
A Selective PI3K Inhibitor Preferentially Inhibits p110α (H1047R) Mutated Cells
Jia-li Liu, Guo-rui Gao, Xi Zhang, Su-fen Cao, Chen-liang Guo, Xiang Wang, Lin-jiang Tong, Jian Ding, Wen-hu Duan and Ling-hua Meng
Journal of Pharmacology and Experimental Therapeutics March 1, 2014, 348 (3) 432-441; DOI: https://doi.org/10.1124/jpet.113.210724
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement